Balyasny Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $149M | Sell |
1,166,000
-884,100
| -43% | -$110M | 0.19% | 97 |
|
|
2025
Q4 | $250M | Sell |
2,050,100
-42,300
| -2% | -$4.85M | 0.32% | 43 |
|
|
2025
Q3 | $210M | Buy |
2,092,400
+608,400
| +41% | +$54.8M | 0.27% | 62 |
|
|
2025
Q2 | $123M | Sell |
1,484,000
-93,900
| -6% | -$7.49M | 0.19% | 112 |
|
|
2025
Q1 | $128M | Sell |
1,577,900
-274,400
| -15% | -$24.5M | 0.21% | 83 |
|
|
2024
Q4 | $167M | Buy |
1,852,300
+151,300
| +9% | +$14.7M | 0.25% | 77 |
|
|
2024
Q3 | $168M | Buy |
1,701,000
+82,000
| +5% | +$8.06M | 0.27% | 63 |
|
|
2024
Q2 | $150M | Buy |
1,619,000
+515,800
| +47% | +$46.2M | 0.26% | 70 |
|
|
2024
Q1 | $105M | Sell |
1,103,200
-45,700
| -4% | -$4.24M | 0.18% | 110 |
|
|
2023
Q4 | $103M | Buy |
1,148,900
+435,600
| +61% | +$32.3M | 0.19% | 102 |
|
|
2023
Q3 | $52.1M | Buy |
713,300
+273,300
| +62% | +$21.8M | 0.11% | 253 |
|
|
2023
Q2 | $36.6M | Buy |
440,000
+311,200
| +242% | +$26M | 0.08% | 339 |
|
|
2023
Q1 | $9.82M | Buy |
128,800
+23,800
| +23% | +$1.97M | 0.02% | 785 |
|
|
2022
Q4 | $8.71M | Buy |
105,000
+20,000
| +24% | +$1.62M | 0.02% | 797 |
|
|
2022
Q3 | $6.74M | Sell |
85,000
-115,000
| -58% | -$9.7M | 0.02% | 871 |
|
|
2022
Q2 | $14.9M | Hold |
200,000
| – | – | 0.05% | 520 |
|
|
2022
Q1 | $18M | Hold |
200,000
| – | – | 0.06% | 457 |
|
|
2021
Q4 | $22.4M | Buy |
+200,000
| New | +$24.1M | 0.08% | 365 |
|
|
2019
Q4 | – | Sell |
-255,000
| Closed | -$19.4M | – | 1540 |
|
|
2019
Q3 | $19.4M | Buy |
255,000
+155,000
| +155% | +$12.9M | 0.13% | 246 |
|
|
2019
Q2 | $8.73M | Buy |
100,000
+50,000
| +100% | +$4.26M | 0.06% | 443 |
|
|
2019
Q1 | $4.53M | Buy |
+50,000
| New | +$4.25M | 0.03% | 586 |
|
|
2018
Q1 | – | Sell |
-130,000
| Closed | -$11M | – | 2364 |
|
|
2017
Q4 | $11M | Buy |
130,000
+105,000
| +420% | +$8.8M | 0.03% | 604 |
|
|
2017
Q3 | $2.16M | Sell |
25,000
-140,000
| -85% | -$11.2M | 0.01% | 936 |
|
|
2017
Q2 | $12.7M | Sell |
165,000
-235,000
| -59% | -$16.7M | 0.05% | 457 |
|
|
2017
Q1 | $27.7M | Buy |
+400,000
| New | +$26.9M | 0.13% | 205 |
|
|
2016
Q3 | – | Sell |
-50,000
| Closed | -$2.7M | – | 1304 |
|
|
2016
Q2 | $2.7M | Sell |
50,000
-300,000
| -86% | -$16.4M | 0.02% | 630 |
|
|
2016
Q1 | $18.1M | Buy |
+350,000
| New | +$18.2M | 0.11% | 269 |
|
|
2015
Q3 | – | Sell |
-90,000
| Closed | -$7.57M | – | 1410 |
|
|
2015
Q2 | $7.57M | Buy |
90,000
+60,000
| +200% | +$4.67M | 0.05% | 481 |
|
|
2015
Q1 | $2.25M | Buy |
+30,000
| New | +$2.1M | 0.02% | 607 |
|
Other funds holding XBI
Balyasny Asset Management's XBI Position: Q1 2026 in Review
Balyasny Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 53,091 shares — an estimated $6.63M sold.
Balyasny Asset Management first reported a position in XBI in Q2 2015 and held it in 19 quarters. The position peaked at $57.2M in Q3 2019. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Balyasny Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 53,091 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $6.63M.
- Balyasny Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and held it in 19 quarters.
- Balyasny Asset Management's State Street SPDR S&P Biotech ETF position peaked at $57.2M in Q3 2019.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.